US5977144A
(en)
*
|
1992-08-31 |
1999-11-02 |
University Of Florida |
Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
|
US7214686B2
(en)
|
1997-06-30 |
2007-05-08 |
Targacept, Inc. |
Pharmaceutical compositions and methods for effecting dopamine release
|
US6632823B1
(en)
*
|
1997-12-22 |
2003-10-14 |
Merck & Co., Inc. |
Substituted pyridine compounds useful as modulators of acetylcholine receptors
|
US6277870B1
(en)
|
1998-05-04 |
2001-08-21 |
Astra Ab |
Use
|
FR2804430B1
(fr)
*
|
2000-01-28 |
2002-03-22 |
Sanofi Synthelabo |
Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
|
GB0010955D0
(en)
|
2000-05-05 |
2000-06-28 |
Novartis Ag |
Organic compounds
|
US8914114B2
(en)
|
2000-05-23 |
2014-12-16 |
The Feinstein Institute For Medical Research |
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
|
US6486172B2
(en)
|
2000-08-18 |
2002-11-26 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
US6492386B2
(en)
*
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
US6492385B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
AU2001282874A1
(en)
*
|
2000-08-18 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
EP1311505A2
(en)
*
|
2000-08-21 |
2003-05-21 |
PHARMACIA & UPJOHN COMPANY |
Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
|
WO2002015662A2
(en)
*
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
|
WO2002017358A2
(en)
*
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
|
PE20021019A1
(es)
|
2001-04-19 |
2002-11-13 |
Upjohn Co |
Grupos azabiciclicos sustituidos
|
AR036041A1
(es)
*
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
|
AR036040A1
(es)
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
|
WO2003018586A1
(en)
*
|
2001-08-24 |
2003-03-06 |
Pharmacia & Upjohn Company |
Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
|
BR0212101A
(pt)
|
2001-08-24 |
2004-08-24 |
Pharmacia & Up John Company |
7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
|
BR0212477A
(pt)
*
|
2001-09-12 |
2004-08-24 |
Upjohn Co |
7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
|
CA2462453C
(en)
*
|
2001-10-02 |
2009-07-28 |
Pharmacia & Upjohn Company |
Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
|
US6849620B2
(en)
|
2001-10-26 |
2005-02-01 |
Pfizer Inc |
N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
|
MXPA04004464A
(es)
|
2001-11-08 |
2004-08-11 |
Upjohn Co |
Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
|
CA2466344A1
(en)
|
2001-11-09 |
2003-05-22 |
Pharmacia & Upjohn Company |
Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
|
US7067261B2
(en)
|
2001-12-14 |
2006-06-27 |
Targacept, Inc. |
Methods and compositions for treatment of central nervous system disorders
|
DE10164139A1
(de)
|
2001-12-27 |
2003-07-10 |
Bayer Ag |
2-Heteroarylcarbonsäureamide
|
WO2003070728A2
(en)
|
2002-02-15 |
2003-08-28 |
Pharmacia & Upjohn Company |
Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
|
US6894042B2
(en)
*
|
2002-02-19 |
2005-05-17 |
Pharmacia & Upjohn Company |
Azabicyclic compounds for the treatment of disease
|
CA2476681A1
(en)
*
|
2002-02-19 |
2003-08-28 |
Bruce N. Rogers |
Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
|
EP1478646A1
(en)
*
|
2002-02-20 |
2004-11-24 |
PHARMACIA & UPJOHN COMPANY |
Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
|
DE10211415A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Bicyclische N-Biarylamide
|
DE10211416A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Essig- und Propionsäureamide
|
US7176198B2
(en)
|
2002-08-01 |
2007-02-13 |
Pfizer Inc. |
1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
|
EP1531820A1
(en)
|
2002-08-30 |
2005-05-25 |
Memory Pharmaceuticals Corporation |
Anabaseine derivatives useful in the treatment of neurodegenerative diseases
|
GB0220581D0
(en)
|
2002-09-04 |
2002-10-09 |
Novartis Ag |
Organic Compound
|
EP1543000B1
(en)
|
2002-09-25 |
2013-03-06 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
|
CA2503786A1
(en)
*
|
2002-11-01 |
2004-05-13 |
Pharmacia & Upjohn Company Llc |
Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases
|
US7238715B2
(en)
*
|
2002-12-06 |
2007-07-03 |
The Feinstein Institute For Medical Research |
Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
|
AU2003298939B2
(en)
*
|
2002-12-06 |
2007-03-15 |
The Feinstein Institute For Medical Research |
Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists
|
MXPA05010496A
(es)
*
|
2003-03-28 |
2005-11-16 |
Pharmacia & Upjohn Co Llc |
Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
|
GB0310867D0
(en)
|
2003-05-12 |
2003-06-18 |
Novartis Ag |
Organic compounds
|
DE10334724A1
(de)
*
|
2003-07-30 |
2005-02-24 |
Bayer Healthcare Ag |
N-Biarylamide
|
ATE451368T1
(de)
|
2003-10-15 |
2009-12-15 |
Targacept Inc |
Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
|
CA2550689A1
(en)
|
2003-12-22 |
2005-07-14 |
Memory Pharmaceuticals Corporation |
Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
|
US20050137217A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Jianguo Ji |
Spirocyclic quinuclidinic ether derivatives
|
JP4995075B2
(ja)
|
2004-03-25 |
2012-08-08 |
メモリー・ファーマシューティカルズ・コーポレイション |
インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用
|
US10912712B2
(en)
|
2004-03-25 |
2021-02-09 |
The Feinstein Institutes For Medical Research |
Treatment of bleeding by non-invasive stimulation
|
ATE487716T1
(de)
|
2004-04-22 |
2010-11-15 |
Memory Pharm Corp |
Indole, 1h-indazole, 1,2-benzisoxazole, 1,2- benzoisothiazole, deren herstellung und verwendungen
|
BRPI0510212A
(pt)
|
2004-05-07 |
2007-10-16 |
Memory Pharm Corp |
1h-indazóis, benzotiazóis, 1,2 - benzoisoxazóis, 1,2-benzoisotiazóis, e cromonas e a preparação e usos dos mesmos
|
AR049401A1
(es)
|
2004-06-18 |
2006-07-26 |
Novartis Ag |
Aza-biciclononanos
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
GB0424564D0
(en)
*
|
2004-11-05 |
2004-12-08 |
Novartis Ag |
Organic compounds
|
WO2006069097A2
(en)
|
2004-12-22 |
2006-06-29 |
Memory Pharmaceuticals Corporation |
Nicotinic alpha-7 receptor ligands and preparation and uses thereof
|
US11207518B2
(en)
|
2004-12-27 |
2021-12-28 |
The Feinstein Institutes For Medical Research |
Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
|
JP2008525102A
(ja)
|
2004-12-27 |
2008-07-17 |
ノース ショア−ロング アイランド ジューウィッシュ リサーチ インスティテュート |
電気的な迷走神経刺激による炎症性障害の処置
|
NZ565628A
(en)
|
2005-08-22 |
2011-03-31 |
Targacept Inc |
Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof
|
US8106066B2
(en)
|
2005-09-23 |
2012-01-31 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
|
GB0521508D0
(en)
|
2005-10-21 |
2005-11-30 |
Novartis Ag |
Organic compounds
|
US8316104B2
(en)
|
2005-11-15 |
2012-11-20 |
California Institute Of Technology |
Method and apparatus for collaborative system
|
GB0525672D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
GB0525673D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
TWI454262B
(zh)
*
|
2006-11-02 |
2014-10-01 |
Targacept Inc |
菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
|
CL2008000119A1
(es)
|
2007-01-16 |
2008-05-16 |
Wyeth Corp |
Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
|
WO2008096870A1
(ja)
*
|
2007-02-09 |
2008-08-14 |
Astellas Pharma Inc. |
アザ架橋環化合物
|
TW200911808A
(en)
*
|
2007-07-23 |
2009-03-16 |
Astrazeneca Ab |
Novel compounds
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
US8391970B2
(en)
|
2007-08-27 |
2013-03-05 |
The Feinstein Institute For Medical Research |
Devices and methods for inhibiting granulocyte activation by neural stimulation
|
DK2217597T3
(da)
|
2007-10-01 |
2011-06-20 |
Comentis Inc |
Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom
|
DK2254598T3
(da)
|
2008-02-13 |
2013-07-29 |
Targacept Inc |
Kombination af alfa 7-nikotinagonister og antipsykotika
|
US9662490B2
(en)
|
2008-03-31 |
2017-05-30 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
|
WO2009146030A1
(en)
|
2008-03-31 |
2009-12-03 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation of t-cell activity
|
EA201001889A1
(ru)
|
2008-06-20 |
2011-08-30 |
Астразенека Аб |
Производные дибензотиазепина и их применение
|
WO2010059617A2
(en)
|
2008-11-18 |
2010-05-27 |
Setpoint Medical Corporation |
Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
AR075183A1
(es)
*
|
2009-01-28 |
2011-03-16 |
Astrazeneca Ab |
Compuestos de 2-aza-biciclo (2,2,1) heptano y sus usos
|
US8886339B2
(en)
|
2009-06-09 |
2014-11-11 |
Setpoint Medical Corporation |
Nerve cuff with pocket for leadless stimulator
|
US9211410B2
(en)
|
2009-05-01 |
2015-12-15 |
Setpoint Medical Corporation |
Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
US8996116B2
(en)
|
2009-10-30 |
2015-03-31 |
Setpoint Medical Corporation |
Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
|
FR2948368B1
(fr)
*
|
2009-07-21 |
2011-07-22 |
Servier Lab |
Nouveaux composes piperidiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US11051744B2
(en)
|
2009-11-17 |
2021-07-06 |
Setpoint Medical Corporation |
Closed-loop vagus nerve stimulation
|
US9833621B2
(en)
|
2011-09-23 |
2017-12-05 |
Setpoint Medical Corporation |
Modulation of sirtuins by vagus nerve stimulation
|
AU2010336337B2
(en)
|
2009-12-23 |
2016-02-04 |
Setpoint Medical Corporation |
Neural stimulation devices and systems for treatment of chronic inflammation
|
WO2011146511A1
(en)
|
2010-05-17 |
2011-11-24 |
Envivo Pharmaceuticals, Inc. |
A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
|
BR112013003847A8
(pt)
|
2010-08-19 |
2017-12-26 |
Buck Institute For Age Res |
métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
|
EP2707094B1
(en)
|
2011-05-09 |
2016-02-03 |
Setpoint Medical Corporation |
Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
GB201111705D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Compounds and their use
|
GB201111704D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Novel compounds
|
JO3115B1
(ar)
|
2011-08-22 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مركبات بيريدازينون واستخدامها كمثبطات daao
|
US9572983B2
(en)
|
2012-03-26 |
2017-02-21 |
Setpoint Medical Corporation |
Devices and methods for modulation of bone erosion
|
AU2013259871A1
(en)
|
2012-05-08 |
2014-11-20 |
Forum Pharmaceuticals Inc. |
Methods of maintaining, treating or improving cognitive function
|
GB201209587D0
(en)
|
2012-05-30 |
2012-07-11 |
Takeda Pharmaceutical |
Therapeutic compounds
|
MA37975B2
(fr)
*
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
WO2014122474A1
(en)
|
2013-02-07 |
2014-08-14 |
Takeda Pharmaceutical Company Limited |
Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
|
CN105189491B
(zh)
*
|
2013-03-15 |
2018-07-06 |
建新公司 |
制备葡萄糖基神经酰胺合酶抑制剂的方法
|
EP3010900B1
(en)
|
2013-06-21 |
2018-01-03 |
Takeda Pharmaceutical Company Limited |
1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
|
GB201314286D0
(en)
|
2013-08-08 |
2013-09-25 |
Takeda Pharmaceutical |
Therapeutic Compounds
|
GB201318222D0
(en)
|
2013-10-15 |
2013-11-27 |
Takeda Pharmaceutical |
Novel compounds
|
GB201320905D0
(en)
|
2013-11-27 |
2014-01-08 |
Takeda Pharmaceutical |
Therapeutic compounds
|
TW201613864A
(en)
|
2014-02-20 |
2016-04-16 |
Takeda Pharmaceutical |
Novel compounds
|
EP3166940A4
(en)
|
2014-07-11 |
2018-04-25 |
Alpharmagen, LLC |
Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity
|
US11311725B2
(en)
|
2014-10-24 |
2022-04-26 |
Setpoint Medical Corporation |
Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
|
WO2016126807A1
(en)
|
2015-02-03 |
2016-08-11 |
Setpoint Medical Corporation |
Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
US10596367B2
(en)
|
2016-01-13 |
2020-03-24 |
Setpoint Medical Corporation |
Systems and methods for establishing a nerve block
|
EP3405255A4
(en)
|
2016-01-20 |
2019-10-16 |
Setpoint Medical Corporation |
IMPLANTABLE MICROSTIMULATORS AND INDUCTION RECHARGE SYSTEMS
|
US10695569B2
(en)
|
2016-01-20 |
2020-06-30 |
Setpoint Medical Corporation |
Control of vagal stimulation
|
US11471681B2
(en)
|
2016-01-20 |
2022-10-18 |
Setpoint Medical Corporation |
Batteryless implantable microstimulators
|
US10583304B2
(en)
|
2016-01-25 |
2020-03-10 |
Setpoint Medical Corporation |
Implantable neurostimulator having power control and thermal regulation and methods of use
|
GB201616839D0
(en)
|
2016-10-04 |
2016-11-16 |
Takeda Pharmaceutical Company Limited |
Therapeutic compounds
|
GB201619514D0
(en)
|
2016-11-18 |
2017-01-04 |
Takeda Pharmaceuticals Co |
Novel compounds
|
DE102017210141A1
(de)
|
2017-06-16 |
2018-12-20 |
Henkel Ag & Co. Kgaa |
Portion zur Bereitstellung tensidhaltiger Flotten
|
US11173307B2
(en)
|
2017-08-14 |
2021-11-16 |
Setpoint Medical Corporation |
Vagus nerve stimulation pre-screening test
|
US11660443B2
(en)
|
2018-04-20 |
2023-05-30 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
|
US11260229B2
(en)
|
2018-09-25 |
2022-03-01 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
|
EP4041734B1
(en)
*
|
2019-11-15 |
2024-04-24 |
Yuhan Corporation |
Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
|
JP2023503830A
(ja)
*
|
2019-11-15 |
2023-02-01 |
ユーハン・コーポレイション |
2,3-ジヒドロ-1h-インデン基もしくは2,3-ジヒドロベンゾフラン基を有する新規な誘導体またはその薬学的に許容可能な塩及びこれらを含む医薬組成物
|
JP2021138648A
(ja)
|
2020-03-04 |
2021-09-16 |
武田薬品工業株式会社 |
経口固形製剤
|
JP2023526080A
(ja)
|
2020-05-21 |
2023-06-20 |
ザ・フェインステイン・インスティチュート・フォー・メディカル・リサーチ |
迷走神経刺激のためのシステムおよび方法
|
AU2021311131A1
(en)
|
2020-07-24 |
2023-03-23 |
Genzyme Corporation |
Pharmaceutical compositions comprising venglustat
|
BR112023022015A2
(pt)
*
|
2021-05-11 |
2023-12-26 |
Green Cross Corp |
Novos compostos que têm atividade inibidora contra glucosilceramida sintase ou sal farmaceuticamente aceitável da mesma, processos para preparar os mesmos e respectivas composições farmacêuticas
|